Passage Bio Inc. (PASG) NASDAQ
$1.31 0.04 (3.15%)
Market Cap: $72.83M
As of 03/27/24 04:00 PM EDT. Market closed.
Passage Bio Inc. (PASG)
NASDAQ
$1.31
0.04 (3.15%)
Market Cap: $72.83M
As of 03/27/24 04:00 PM EDT. Market closed.
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã?-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to ... read more
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã?-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Borthwick Kathleen | SVP, INTERIM CFO | Feb 13, 2024 | Sale | $0.97 | 1,470 | 1,426 | 28,466 | Feb 13, 2024, 07:36 PM |
Forman Mark S | CHIEF MEDICAL OFFICER | Feb 13, 2024 | Sale | $0.97 | 1,638 | 1,589 | 48,631 | Feb 13, 2024, 07:34 PM |
King Simona | Chief Financial Officer | Jul 28, 2023 | Sale | $0.88 | 11,453 | 10,079 | 23,994 | Aug 01, 2023, 04:36 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jun 28, 2023 | Buy | $0.84 | 575,195 | 483,164 | 8,034,000 | Jun 29, 2023, 04:42 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jun 27, 2023 | Buy | $0.84 | 617,382 | 518,601 | 7,458,805 | Jun 29, 2023, 04:42 PM |
Fotopoulos Alexandros | Chief Technical Officer | Jun 16, 2023 | Sale | $0.93 | 4,052 | 3,778 | 28,693 | Jun 20, 2023, 04:10 PM |
King Simona | Chief Financial Officer | Apr 18, 2023 | Sale | $1.05 | 2,053 | 2,156 | 2,053 | Apr 20, 2023, 04:28 PM |
Kapadia Sandip | Director | Dec 01, 2022 | Sale | $1.19 | 5,000 | 5,964 | 0 | Dec 02, 2022, 05:14 PM |
Fotopoulos Alexandros | Chief Technical Officer | Nov 22, 2022 | Sale | $1.33 | 3,720 | 4,948 | 20,245 | Nov 25, 2022, 04:15 PM |
Toernsen Monika Maria | Chief Commercial Officer | Sep 19, 2022 | Sale | $1.51 | 1,681 | 2,539 | 3,319 | Nov 18, 2022, 05:01 PM |
ORBIMED ADVISORS LLC | 10% Owner | May 04, 2022 | Buy | $1.94 | 303,500 | 588,790 | 6,841,423 | May 05, 2022, 05:23 PM |
ORBIMED ADVISORS LLC | 10% Owner | May 03, 2022 | Buy | $1.93 | 221,500 | 427,495 | 6,537,923 | May 05, 2022, 05:23 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 20, 2022 | Buy | $5.00 | 50,800 | 254,000 | 6,316,423 | May 05, 2022, 05:11 PM |
Goldsmith Bruce A | CEO and President | Mar 21, 2022 | Buy | $3.15 | 10,000 | 31,500 | 15,983 | Mar 23, 2022, 04:43 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 20, 2022 | Buy | $5.42 | 369,100 | 2,000,522 | 6,634,723 | Jan 24, 2022, 04:44 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 19, 2022 | Buy | $5.11 | 43,300 | 221,263 | 6,265,623 | Jan 20, 2022, 06:03 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 18, 2022 | Buy | $5.46 | 114,700 | 626,262 | 6,222,323 | Jan 20, 2022, 06:03 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 14, 2022 | Buy | $5.60 | 10,300 | 57,680 | 6,107,623 | Jan 20, 2022, 06:03 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 13, 2022 | Buy | $5.52 | 41,800 | 230,736 | 6,097,323 | Jan 13, 2022, 07:37 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 12, 2022 | Buy | $5.65 | 100,000 | 565,000 | 6,055,523 | Jan 13, 2022, 07:37 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 11, 2022 | Buy | $5.53 | 8,200 | 45,346 | 5,955,523 | Jan 13, 2022, 07:37 PM |
Quigley Jill M. | Chief Operating Officer | Dec 08, 2021 | Option Exercise | $0.23 | 71,975 | 16,554 | 368,754 | Dec 10, 2021, 05:30 PM |
Romano Gary | Chief Medical Officer | Mar 15, 2021 | Option Exercise | $8.07 | 10,000 | 80,700 | 10,000 | Mar 17, 2021, 09:12 PM |
Romano Gary | Chief Medical Officer | Mar 15, 2021 | Sale | $21.10 | 10,000 | 211,013 | 1,617 | Mar 17, 2021, 09:12 PM |
Quigley Jill M. | Chief Operating Officer | Jan 20, 2021 | Sale | $30.01 | 1,300 | 39,011 | 295,284 | Jan 22, 2021, 05:54 PM |
Quigley Jill M. | Chief Operating Officer | Jan 14, 2021 | Sale | $30.10 | 16,298 | 490,570 | 296,584 | Jan 15, 2021, 08:29 PM |
Countouriotis Athena | Director | Mar 24, 2020 | Buy | $14.98 | 10,000 | 149,750 | 18,900 | Mar 25, 2020, 08:26 PM |
Ratcliffe Liam | Director | Mar 03, 2020 | Buy | $18.00 | 2,800 | 50,400 | 2,800 | Mar 13, 2020, 05:20 PM |
Ratcliffe Liam | Director | Mar 03, 2020 | Buy | $18.00 | 550,000 | 9,900,000 | 2,616,630 | Mar 13, 2020, 05:20 PM |
ORBIMED ADVISORS LLC | 10% Owner | Feb 28, 2020 | Buy | $18.00 | 373,300 | 6,719,400 | 373,300 | Mar 03, 2020, 07:07 PM |
Versant Venture Capital VI, L.P. | 10% Owner | Mar 03, 2020 | Buy | $18.00 | 225,000 | 4,050,000 | 933,352 | Mar 03, 2020, 07:03 PM |
Frazier Life Sciences IX, L.P. | 10% Owner | Mar 03, 2020 | Buy | $18.00 | 550,000 | 9,900,000 | 5,009,219 | Mar 03, 2020, 06:59 PM |
Woiwode Thomas | Director | Mar 03, 2020 | Buy | $18.00 | 225,000 | 4,050,000 | 933,352 | Mar 03, 2020, 06:57 PM |
Heron Patrick J | Director | Mar 03, 2020 | Buy | $18.00 | 550,000 | 9,900,000 | 5,009,219 | Mar 03, 2020, 06:54 PM |
Yamada Tadataka | Director | Mar 03, 2020 | Buy | $18.00 | 6,500 | 117,000 | 656,149 | Mar 03, 2020, 06:51 PM |
Ratcliffe Liam | Director | Mar 03, 2020 | Buy | $18.00 | 2,800 | 50,400 | 2,800 | Mar 03, 2020, 06:48 PM |
Quigley Jill M. | Chief Operating Officer | Mar 03, 2020 | Buy | $18.00 | 1,000 | 18,000 | 1,000 | Mar 03, 2020, 06:46 PM |
Quigley Jill M. | Chief Operating Officer | Mar 03, 2020 | Buy | $18.00 | 1,500 | 27,000 | 311,494 | Mar 03, 2020, 06:46 PM |
Morris Richard Steven | Chief Financial Officer | Mar 03, 2020 | Buy | $18.00 | 400 | 7,200 | 400 | Mar 03, 2020, 06:44 PM |
Kapadia Sandip | Director | Mar 03, 2020 | Buy | $18.00 | 5,000 | 90,000 | 5,000 | Mar 03, 2020, 06:43 PM |
Islam Saqib | Director | Mar 03, 2020 | Buy | $18.00 | 5,000 | 90,000 | 5,000 | Mar 03, 2020, 06:41 PM |
Goldsmith Bruce A | CEO and President | Mar 03, 2020 | Buy | $18.00 | 1,100 | 19,800 | 1,100 | Mar 03, 2020, 06:40 PM |
Fotopoulos Alexandros | Chief Technical Officer | Mar 03, 2020 | Buy | $18.00 | 5,500 | 99,000 | 5,500 | Mar 03, 2020, 06:38 PM |
Countouriotis Athena | Director | Mar 03, 2020 | Buy | $18.00 | 8,900 | 160,200 | 8,900 | Mar 03, 2020, 06:37 PM |
Cale Edgar B. | GC and Corporate Secretary | Mar 03, 2020 | Buy | $18.00 | 2,000 | 36,000 | 2,000 | Mar 03, 2020, 06:35 PM |
Owner | Relationship | Date | Value($) |
Borthwick Kathleen | SVP, INTERIM CFO | 02/13/2024 | 1,426 |
Forman Mark S | CHIEF MEDICAL OFFICER | 02/13/2024 | 1,589 |
King Simona | Chief Financial Officer | 07/28/2023 | 10,079 |
ORBIMED ADVISORS LLC | 10% Owner | 06/28/2023 | 483,164 |
ORBIMED ADVISORS LLC | 10% Owner | 06/27/2023 | 518,601 |
Fotopoulos Alexandros | Chief Technical Officer | 06/16/2023 | 3,778 |
King Simona | Chief Financial Officer | 04/18/2023 | 2,156 |
Kapadia Sandip | Director | 12/01/2022 | 5,964 |
Fotopoulos Alexandros | Chief Technical Officer | 11/22/2022 | 4,948 |
Toernsen Monika Maria | Chief Commercial Officer | 09/19/2022 | 2,539 |
ORBIMED ADVISORS LLC | 10% Owner | 05/04/2022 | 588,790 |
ORBIMED ADVISORS LLC | 10% Owner | 05/03/2022 | 427,495 |
ORBIMED ADVISORS LLC | 10% Owner | 01/20/2022 | 254,000 |
Goldsmith Bruce A | CEO and President | 03/21/2022 | 31,500 |
ORBIMED ADVISORS LLC | 10% Owner | 01/20/2022 | 2,000,522 |
ORBIMED ADVISORS LLC | 10% Owner | 01/19/2022 | 221,263 |
ORBIMED ADVISORS LLC | 10% Owner | 01/18/2022 | 626,262 |
ORBIMED ADVISORS LLC | 10% Owner | 01/14/2022 | 57,680 |
ORBIMED ADVISORS LLC | 10% Owner | 01/13/2022 | 230,736 |
ORBIMED ADVISORS LLC | 10% Owner | 01/12/2022 | 565,000 |
ORBIMED ADVISORS LLC | 10% Owner | 01/11/2022 | 45,346 |
Quigley Jill M. | Chief Operating Officer | 12/08/2021 | 16,554 |
Romano Gary | Chief Medical Officer | 03/15/2021 | 80,700 |
Romano Gary | Chief Medical Officer | 03/15/2021 | 211,013 |
Quigley Jill M. | Chief Operating Officer | 01/20/2021 | 39,011 |
Quigley Jill M. | Chief Operating Officer | 01/14/2021 | 490,570 |
Countouriotis Athena | Director | 03/24/2020 | 149,750 |
Ratcliffe Liam | Director | 03/03/2020 | 50,400 |
Ratcliffe Liam | Director | 03/03/2020 | 9,900,000 |
ORBIMED ADVISORS LLC | 10% Owner | 02/28/2020 | 6,719,400 |
Versant Venture Capital VI, L.P. | 10% Owner | 03/03/2020 | 4,050,000 |
Frazier Life Sciences IX, L.P. | 10% Owner | 03/03/2020 | 9,900,000 |
Woiwode Thomas | Director | 03/03/2020 | 4,050,000 |
Heron Patrick J | Director | 03/03/2020 | 9,900,000 |
Yamada Tadataka | Director | 03/03/2020 | 117,000 |
Ratcliffe Liam | Director | 03/03/2020 | 50,400 |
Quigley Jill M. | Chief Operating Officer | 03/03/2020 | 18,000 |
Quigley Jill M. | Chief Operating Officer | 03/03/2020 | 27,000 |
Morris Richard Steven | Chief Financial Officer | 03/03/2020 | 7,200 |
Kapadia Sandip | Director | 03/03/2020 | 90,000 |
Islam Saqib | Director | 03/03/2020 | 90,000 |
Goldsmith Bruce A | CEO and President | 03/03/2020 | 19,800 |
Fotopoulos Alexandros | Chief Technical Officer | 03/03/2020 | 99,000 |
Countouriotis Athena | Director | 03/03/2020 | 160,200 |
Cale Edgar B. | GC and Corporate Secretary | 03/03/2020 | 36,000 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 10,124,576 | 0.2% | No change | Other |
RENAISSANCE TECHNOLOGIES LLC | 1,223,351 | 0.00191% | 23.02% | Other |
BLACKROCK INC. | 1,022,563 | 0.00003% | 1.01% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 332,203 | 0.00004% | No change | Other |
D. E. SHAW & CO., INC. | 10,026 | 0.00001% | Exited | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View